Effects of Pubertal Exposure to Butyl Benzyl Phthalate, Perfluorooctanoic Acid, and Zeranol on Mammary Gland Development and Tumorigenesis in Rats.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Jan 2022
Historique:
received: 22 12 2021
revised: 18 01 2022
accepted: 24 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 9 4 2022
Statut: epublish

Résumé

Endocrine-disrupting chemicals (EDCs)-including butyl benzyl phthalate (BBP), perfluorooctanoic acid (PFOA), and zeranol (α-ZAL, referred to as ZAL hereafter)-can interfere with the endocrine system and produce adverse effects. It remains unclear whether pubertal exposure to low doses of BBP, PFOA, and ZAL has an impact on breast development and tumorigenesis. We exposed female Sprague Dawley rats to BBP, PFOA, or ZAL through gavage for 21 days, starting on day 21, and analyzed their endocrine organs, serum hormones, mammary glands, and transcriptomic profiles of the mammary glands at days 50 and 100. We also conducted a tumorigenesis study for rats treated with PFOA and ZAL using a 7,12-dimethylbenz[a]anthracene (DMBA) model. Our results demonstrated that pubertal exposure to BBP, PFOA, and ZAL affected endocrine organs and serum hormones, and induced phenotypic and transcriptomic changes. The exposure to PFOA + ZAL induced the most phenotypic and transcriptomic changes in the mammary gland. PFOA + ZAL downregulated the expression of genes related to development at day 50, whereas it upregulated genes associated with tumorigenesis at day 100. PFOA + ZAL exposure also decreased rat mammary tumor latency, reduced the overall survival of rats after DMBA challenge, and affected the histopathology of mammary tumors. Therefore, our study suggests that exposure to low doses of EDCs during the pubertal period could induce changes in the endocrine system and mammary gland development in rats. The inhibition of mammary gland development by PFOA + ZAL might increase the risk of developing mammary tumors through activation of signaling pathways associated with tumorigenesis.

Identifiants

pubmed: 35163327
pii: ijms23031398
doi: 10.3390/ijms23031398
pmc: PMC8835802
pii:
doi:

Substances chimiques

Caprylates 0
Endocrine Disruptors 0
Fluorocarbons 0
Hormones 0
Phthalic Acids 0
9,10-Dimethyl-1,2-benzanthracene 57-97-6
Zeranol 76LO2L2V39
perfluorooctanoic acid 947VD76D3L
butylbenzyl phthalate YPC4PJX59M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Institute of Health
ID : U01ES026130
Organisme : NCI NIH HHS
ID : P30-CA006927
Pays : United States

Références

EFSA J. 2019 Dec 11;17(12):e05838
pubmed: 32626195
PLoS One. 2014 Sep 02;9(9):e106245
pubmed: 25181051
Cell. 1988 Sep 9;54(6):831-40
pubmed: 2842066
Cancer Lett. 1985 Aug;28(1):77-83
pubmed: 4027959
J Appl Toxicol. 2018 May;38(5):688-695
pubmed: 29250801
Br J Ind Med. 1989 May;46(5):341-6
pubmed: 2751933
J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):211-25
pubmed: 11149574
Environ Health. 2019 Mar 22;18(1):24
pubmed: 30902092
Cancers (Basel). 2016 Jul 13;8(7):
pubmed: 27420097
Toxicol Sci. 2010 May;115(1):214-24
pubmed: 20118188
Environ Sci Technol. 2010 May 1;44(9):3572-9
pubmed: 20377175
J Cancer. 2018 Feb 11;9(4):757-766
pubmed: 29556333
J Toxicol Pathol. 2009 Jun;22(2):109-24
pubmed: 22271984
Reprod Toxicol. 2000 Nov-Dec;14(6):513-32
pubmed: 11099877
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5744-9
pubmed: 22451941
Endocrinology. 2017 Jun 1;158(6):1727-1738
pubmed: 28324068
Environ Health Perspect. 2005 Oct;113(10):1399-404
pubmed: 16203254
Mol Cancer. 2018 Feb 19;17(1):45
pubmed: 29455668
In Vivo. 2005 May-Jun;19(3):487-94
pubmed: 15875766
Int J Hyg Environ Health. 2020 Sep;230:113624
pubmed: 33011057
Genes Dev. 2000 Mar 15;14(6):650-4
pubmed: 10733525
Cancer Res. 2017 Apr 15;77(8):2148-2160
pubmed: 28209621
Anticancer Res. 2011 May;31(5):1659-65
pubmed: 21617224
Biol Reprod. 2000 Sep;63(3):905-12
pubmed: 10952938
Environ Res. 2019 Dec;179(Pt A):108743
pubmed: 31542491
Exp Toxicol Pathol. 2012 May;64(4):321-32
pubmed: 20951558
BMC Genomics. 2007 Dec 06;8:453
pubmed: 18062813
J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):31-42
pubmed: 10791766
Am J Epidemiol. 2012 Nov 15;176(10):909-17
pubmed: 23079607
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Environ Health Perspect. 1999 Feb;107 Suppl 1:89-108
pubmed: 10229711
Breast Cancer Res. 2015 Feb 18;17:14
pubmed: 25848982
Environ Health. 2020 Nov 26;19(1):127
pubmed: 33243245
Mol Reprod Dev. 2009 Aug;76(8):733-50
pubmed: 19484750
J Mammary Gland Biol Neoplasia. 2013 Mar;18(1):43-61
pubmed: 23417729
Reprod Toxicol. 2009 Jun;27(3-4):299-306
pubmed: 19013232
Dev Dyn. 2006 Dec;235(12):3404-12
pubmed: 17039550
Toxicol Sci. 2000 Dec;58(2):350-65
pubmed: 11099647
Endocrinology. 2004 Jul;145(7):3106-10
pubmed: 15059953
Reprod Toxicol. 2009 Jun;27(3-4):289-298
pubmed: 19095057
Environ Health Perspect. 2011 Aug;119(8):1070-6
pubmed: 21501981
Environ Health. 2011 Jan 17;10(1):5
pubmed: 21241498
Environ Health Perspect. 2012 May;120(5):668-73
pubmed: 22306490
Pathol Res Pract. 2017 May;213(5):441-446
pubmed: 28285967
Toxicol Pathol. 2015 Feb;43(2):145-70
pubmed: 25714400
Dev Cell. 2015 Sep 14;34(5):493-504
pubmed: 26321127
Cell Stem Cell. 2008 Oct 9;3(4):429-41
pubmed: 18940734
Toxicol Sci. 2011 Jul;122(1):134-45
pubmed: 21482639
Endocrinology. 2006 Jun;147(6 Suppl):S18-24
pubmed: 16690811
Endocrinology. 1999 Jan;140(1):454-61
pubmed: 9886857
Reprod Toxicol. 2017 Mar;68:200-206
pubmed: 27592399
Environ Int. 2020 Oct;143:105970
pubmed: 32763629
Toxicol Lett. 2019 Oct 10;314:53-62
pubmed: 31319113
Reprod Toxicol. 2012 Jul;33(4):563-576
pubmed: 22414604
Sci Total Environ. 2011 Nov 15;409(24):5221-7
pubmed: 21975003
J Steroid Biochem Mol Biol. 2007 Feb;103(2):170-7
pubmed: 17097287
Oncotarget. 2016 Sep 27;7(39):64289-64299
pubmed: 27588403
J Natl Cancer Inst. 2007 Apr 18;99(8):616-27
pubmed: 17440163
Environ Health Perspect. 2000 Oct;108(10):979-82
pubmed: 11049818
In Vivo. 2004 Nov-Dec;18(6):755-61
pubmed: 15646816
Mol Cell Endocrinol. 2012 May 22;355(2):201-7
pubmed: 22227557
Toxicol Ind Health. 2015 Dec;31(12):1296-303
pubmed: 23833243
Cold Spring Harb Perspect Biol. 2011 Mar 01;3(3):
pubmed: 21123394
Chemosphere. 2015 Jun;128:1-6
pubmed: 25602441
Breast Cancer Res. 2010;12(4):208
pubmed: 20804567
Regul Toxicol Pharmacol. 1997 Aug;26(1 Pt 1):102-18
pubmed: 9339487
Mol Cell Biol. 1999 Oct;19(10):7203-15
pubmed: 10490655
Chemosphere. 2017 Oct;184:687-693
pubmed: 28633063
Reprod Toxicol. 2015 Jul;54:26-36
pubmed: 25499722
Am J Pathol. 2008 Sep;173(3):824-34
pubmed: 18688034
Toxicol Sci. 2007 Mar;96(1):133-44
pubmed: 17132714
Environ Int. 2016 Sep;94:51-59
pubmed: 27209000
Int J Stem Cells. 2020 Mar 30;13(1):55-64
pubmed: 32114743
Anticancer Res. 2011 Feb;31(2):481-6
pubmed: 21378327
Mol Med Rep. 2019 Mar;19(3):1645-1653
pubmed: 30592274
Environ Int. 2019 Apr;125:350-364
pubmed: 30743143
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14
pubmed: 19567831
Int J Biol Sci. 2021 Jan 1;17(1):247-258
pubmed: 33390847

Auteurs

Yanrong Su (Y)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Julia Santucci-Pereira (J)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Nhi M Dang (NM)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Joice Kanefsky (J)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Vishnuprabha Rahulkannan (V)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Meardey Hillegass (M)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Shalina Joshi (S)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Hafsa Gurdogan (H)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Zhen Chen (Z)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Vincent Bessonneau (V)

Silent Spring Institute, 320 Nevada Street, Suite 302, Newton, MA 02460, USA.

Ruthann Rudel (R)

Silent Spring Institute, 320 Nevada Street, Suite 302, Newton, MA 02460, USA.

Jennifer Ser-Dolansky (J)

Pioneer Valley Life Sciences Institute, UMASS Chan Medical School-Baystate, Springfield, MA 01199, USA.

Sallie S Schneider (SS)

Pioneer Valley Life Sciences Institute, UMASS Chan Medical School-Baystate, Springfield, MA 01199, USA.

Jose Russo (J)

The Irma H Russo, MD-Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH